SDC1 and melanoma: Recently we established a possible role of SDC1 in VM of melanoma and that combined therapy could improve the therapeutic efficacy of both anti-SDC1 scFv OC-46F2 antibody and immunocytokine L19-IL2, specific for B-FN, administered as single agents [25,36].